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Edited by Michael R. BubbAbstract Understanding the diﬀerences between murine (m)
and human (h) proteinase 3 (PR3) and neutrophil elastase
(NE) is crucial for the interpretation of in vivo studies of inﬂam-
matory processes. We built structural models of mPR3 and mNE
and analyzed their surface properties. We performed molecular
dynamics (MD) simulations on several enzyme–peptide com-
plexes to investigate their interaction patterns. The analysis of
trajectories conﬁrms that murine and human complexes have dif-
ferent interaction patterns with peptidic substrates. We provide a
map of the binding sites of the murine proteases and suggest
sequence motifs that we predict to be speciﬁc for mPR3 or mNE.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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models1. Introduction
Proteinase 3 (PR3) and neutrophil elastase (NE), serine
proteinases of polymorphonuclear neutrophils (PMN) are
involved in inﬂammation processes and are associated with
several diseases [1]. They are involved in proteolytic degrada-
tion of connective tissues [2] and are associated with several
inﬂammatory diseases such as emphysema [3], cystic ﬁbrosis,
rheumatoid arthritis and vasculitis [4]. Although PR3 and
NE have been for a long time thought to have similar localiza-
tion, ligand speciﬁcity and function they might have very dif-
ferent physiologic roles. Speciﬁcally, PR3 behaves as a
peripheral membrane protein [5,6] and its membrane expres-
sion is a risk factor in chronic inﬂammatory diseases [4]. It
has also been shown that human PR3 (hPR3), unlike hNE,
has intracellular speciﬁc protein substrates resulting in the
involvement of hPR3 in regulation of intracellular functions
such as proliferation [7] or apoptosis [8]. In addition hPR3 is
a primary target antigen of the anti-neutrophil cytoplasmic
autoantibodies (ANCA) in the Wegener’s (WG) disease. Mur-
ine models have been increasingly used to investigate the func-
tion of PR3 and HNE (e.g. [9,10]) and in particular the role of*Corresponding author. Fax: +47 555 84295.
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doi:10.1016/j.febslet.2007.11.029PR3 in WG disease (e.g. [9–11]). However, ANCAs from WG
patients do not cross-react with mouse PR3 (mPR3) [12], there
exist no evidence of mPR3 being expressed at the plasma mem-
brane and diﬀerences in the physico-chemical properties of the
mouse and human enzyme has been recently pointed out [13],
in particular diﬀerences in enzymatic eﬃciency and inhibitor
speciﬁcity. Obviously the understanding and interpretation of
in vivo experiments performed in mice and rats require a care-
ful evaluation of the substrate speciﬁcity diﬀerences between (i)
the murine and human serine proteases and (ii) mPR3 and
mNE. So does the development of a reliable murine model
for the study of the function of PR3 in inﬂammation processes
or diseases.
hPR3 and hNE share a high sequence identity and PR3 has
wrongly been classiﬁed as an elastase-like protease [14]. Early
studies focused on the P1 speciﬁcity and revealed the prefer-
ence of PR3 for small hydrophobic amino acids [15]. It is only
recently that the importance of the S 0–P 0 interactions has been
clearly established [16–20] (recognition sites denominated
using the Schechter and Berger nomenclature [21]). It was
shown that peptides extending beyond P1 0 have a favorable
eﬀect on PR3 catalysis but not on NE catalysis. We recently
used molecular modeling to characterize the interactions
between hPR3 and a series of long peptidic substrates
[19,20,22]. We mapped the substrate binding sites and pro-
posed a sequence motif speciﬁc for hPR3: (i) hydrophobic ami-
no acids at P4 and P3, (ii) carboxyl group at P2, (iii) small
hydrophobic group at P1, (iv) basic aminoacid at P1 0 and
P3 0 and (v) carboxyl group at P2 0 (Fig. 1A). Our predictions
were assessed by enzymatic assays using the peptide VAD-
VKDR [19]. This pattern of amino acids corresponds to the
cleavage region of p21waf1 by PR3 [22].
Recently, Specks and co-workers demonstrated that the
mouse and human enzymes have diﬀerent physicochemical
properties. Using inhibitors and short hydrophobic peptides
(not extending in the P 0 sites) they show that they have diﬀer-
ent substrate speciﬁcities [13]. Unfortunately, the size and the
nature of the peptides limit the conclusions to the P1 sites.
The lack of structural information on the murine enzymes
and on their complexes with cleavable peptides makes it diﬃ-
cult to discuss the basis for their substrate speciﬁcity. Molecu-
lar modeling is the method of choice to investigate protein-
substrate interactions at the atomic level of details [23]. We
used homology modeling and molecular dynamics simulations
to build structural models of the murine enzymes and investi-
gate their substrate binding sites, following the strategy used inblished by Elsevier B.V. All rights reserved.
Fig. 1. Map of the recognition sites of hPR3 (A) and alignment of the
sequences (chymotrypsin numbering) of human and mouse PR3 (B)
and of mouse PR3 and NE (C). Bold letters are used for the positions
of residues known to be important for hPR3 speciﬁcity [19], while stars
indicate the conserved residues between pairs of sequences.
Table 1
Peptides used in MD simulations, in complex with hPR3 (a), hNE (b),
mPR3 (c) or mNE (d)
Peptide name Sequence
Pept1 VADVKDR1,a,b,c,d
Pept2 VARVRDRa,c
Pept3 RDVARVKDRQEGc,d
Pept4 RDVARCRDRQEGc,d
Pept5 RDVARCRDRQQGc,d
Pept6 DRDAVDRDIDc,d
Pept7 GDVAVYEENc,d
1Simulations with hPR3 and hNE published in Ref. [19].
5686 E. Hajjar et al. / FEBS Letters 581 (2007) 5685–5690Refs. [19,20,22]. In particular, we mapped the interactions of
seven long peptides, extending both on the P and P 0 sides
(up to P6 and P6 0), with mPR3 and mNE. We present an
inventory of the amino acids constituting the substrate binding
sites of human and mouse PR3 to ﬁnally suggest sequence mo-
tifs that should diﬀerentiate between mPR3 and mNE.Fig. 2. Details of the sequence alignment of hPR3, mPR3, hNE, mNE.
Cf legend of Fig. 1.2. Methods
2.1. Homology modeling
The three-dimensional models of the mouse PR3 and NE were built
with the program Modeller [24] using as templates the three-dimen-
sional structures of the hPR3 (pdb id: lfuj) and hNE (lppf), respec-
tively. We also built the models of rat PR3 and NE. Because of their
extremely high similarity with the mouse variants, our investigation fo-
cuses on the latter.
2.2. Structural properties
The program CASTp [25] was used to identify the S1 pockets in each
enzyme and calculate their volumes. Calculations were done on the
models for the mouse enzymes and on the X-ray structures for the
human enzymes. The electrostatic potential of each protease was calcu-
lated using GRASP [26].2.3. Substrates docking
The peptides were docked in the four enzymes as described previ-
ously [19,20]. Sequences of the peptides are given in Table 1. Peptide
1 is known to be speciﬁc of hPR3 vs hNE [19]. The other peptides
are the result of a rational design based on (i) data on hPR3 and
hNE speciﬁcity, (ii) sequence alignments of the four enzymes and
(iii) the observation of the electrostatic surface potential maps, with
the goal of ﬁtting to either mPR3 (peptides 2–5) or mNE (peptides 6
and 7). In particular, we extended the sequences beyond P3 and P3 0
to explore their inﬂuence on speciﬁcity. All peptides have acetylated
N-terminus and amidated C-terminus and an extra glycine in the ﬁrst
and last positions to minimize the eﬀect of the terminal groups on the
recognition pockets.
2.4. Molecular dynamics simulations
The structure of the enzymes were optimized with Charmm [27], sol-
vated in a pre-equilibrated box of water and simulated with Namd [28].
Based on pKa calculations on free and substrate-bound enzymes using
the UHBD program [29] and the PKALK package [30], the carboxyl
group of Asp213 was protonated in mPR3 but not in mNE. The com-
plexes listed in Table 1 were simulated following the procedure de-
scribed in [19]. All calculations used the Charmm forceﬁeld [31]. The
analyses of the trajectories were performed using Charmm as described
in Ref. [19].3. Results and discussion
3.1. Sequence and structure comparison
The sequences of hPR3 and mPR3 are highly identical (63%
identity, Fig. 1B). Similarly hNE and mNE are 69% identical.
mPR3 and mNE share 50% sequence identity (Fig. 1C), which
is equivalent to the degree of similarity between hPR3 and
hNE (53%). Most of the amino acids thought to be involved
in substrate recognition for hPR3 are conserved in mPR3
(Fig. 1A) [19,20].
The diﬀerences between mPR3 and hPR3 concern mostly the
S2 and S4 sites (cf. Fig. 2). Besides the recognition sites, several
charged residues of hPR3 are substituted in mPR3 by hydro-
phobic or polar amino acids and the other way around, like
for example G38R and R74L. The S1 pocket of mNE is ex-
pected to be more polar than in hNE because of the presence
E. Hajjar et al. / FEBS Letters 581 (2007) 5685–5690 5687of Asp213, at the bottom of the pocket, like for both forms of
PR3. Because of the presence of R143 in the S2 site of mNE
the P2 0 position can probably not be used to discriminate be-
tween mNE and mPR3, as it was done to discriminate between
their human homologues [16,18]. mPR3 and mNE diﬀer
mostly in regions of the sequence involved in sites P4, P2,
P1 0 and P3 0 (cf. Fig. 2).
3.2. Surface electrostatics
The surface of mPR3 is globally more electronegative than
the one of hPR3 (Fig. 3). This is particularly true for the ligand
binding sites (Fig. 4). The reason is the substitution of basic
amino acids of hPR3 around the peptide-binding site: R60Q,
R63bQ, R74L, N98E, K99N, G219E. Unlike hPR3, mPR3 is
thus unlikely to bind substrates with acidic groups (Asp,
Glu) on the S side. The diﬀerences between mNE and hNE
are less signiﬁcant on the overall protein (Fig. 3). However,
the presence of R35, R36, R74 and R143, renders the S 0 sites
of mNE highly electropositive.
3.3. Volume of the SI pocket
SI pockets of both hPR3 and mPR3 are constituted by the
same residues and are almost of the same size: 98.6 A˚3 and
96.1 A˚3, respectively. The S1 pockets of both forms of NE
are larger than the ones of PR3, 142.8 A˚3 and 152.7 A˚3 for
mNE and hNE, respectively. The diﬀerence between hNE
and mNE is presumably caused by the A213D substitution.Fig. 3. Electrostatic potential for hPR3 (A), mPR3 (B), hNE (C) and mNE (D
enzyme and colored in blue (+5 kT), white (0 kT) and red (5 kT). We also
1 kT (transparent red).3.4. MD simulations of the Michaelis complexes
We ﬁrst investigated the interaction of mPR3 with the pep-
tide we designed to be speciﬁc for hPR3 [19]. The interaction
plot of VADVKDR with mPR3 (Fig. 5A) shows the eﬀects
of the highly electronegative character of the S sites (Fig. 4A
and B); P2–D is repulsed and exposed to solvent. Additionally,
this perturbs the triad and the S 01 site where P1 0–K does not
ﬁnd D61. The interaction plots with mNE reveals its ability,
unlike hNE, to interact with an acidic residue at P2 0, thanks
to R143. Interactions with other charged groups of Peptl are
inexistent. Both mouse enzymes present an interaction between
atom H57-NE2 and the backbone of the peptide, which com-
petes with the crucial H57-Sl95 hydrogen bond (hbond) and
might decrease the catalytic eﬃciency; the hbond between
S195 and H57 is present less than 50% of the simulation time.
We do not expect Peptl to bind strongly to either mPR3 or
mNE in vitro. The observation of the electrostatic surface
potential led us to replace P2-D of Peptl by a positive charge,
resulting in Pept2 (GVARVRDRG). We thus analyzed the
mPR3–Pept2 complex. The interaction plot with mPR3
(Fig. 6) shows strong backbone-backbone interactions: P5-G
with R218, P3-A with V216, P1-V with G193 and S195 (oxyan-
ion hole) and S214, P2 0–D with F41. Regarding the side chains
interactions, we observe that P2–R interacts with N99-OD1 and
Y94-OH.Pl–Vﬁnds its usual hydrophobic partner (Val216). Ex-
cept for P3 0–S3 0 the P 0–S 0 interactions are optimal; Pl 0–R and
P2 0–D make strong hbonds with D61 and R143, respectively.). The electrostatic potential is mapped on the molecular surface of the
represent the equipotential contours at +1 kT (transparent blue) and
Fig. 4. Active site and recognition pockets of the complexes hPR3-peptl (A) and mPR3-pept2, (B) cf. Fig. 3. Amino acids of the peptide are colored
according to their type (blue: basic, red: acidic, white: others).
Fig. 5. Interaction plot of Peptl with mPR3 (A) and mNE (B). Atoms
involved (X-axis) and interactions lifetime (Y-axis). Black bars
represent h-bonds, grey bars represent the lifetime of hydrophobic
contacts. Hashed bars signify interactions involving side-chains of the
peptide, while non-hashed are used for interactions involving the
backbone of the peptide.
Fig. 6. Interaction plot of Pept2 with mPR3. See legend of Fig. 5.
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RDVARVKDRQEG, RDVARCRDRQEG, RDVARCRD-
RQQG (Table 1). We observe that the side chain of P6-R inter-acts with E97 and the carboxyl group of P5-D with R218. The
latter being a tryptophan (W218) in hPR3 the nature of the P5
site is diﬀerent in the mouse and human variants. P5-D and
R218 form also strong hbonds between their backbone atoms.
On the P 0 side, the interactions are similar to the ones observed
for Pept2, and there are no strong side chain-side chain inter-
actions after P3 0. However, strong backbone–backbone inter-
actions are formed between H40 and P4 0. Peptides 6 and 7
were designed to explore the binding sites of mNE. Both make
strong backbone–backbone interactions with the enzyme. The
simulations of Pept6 (cf. Fig. 7) reveal a strong interaction net-
work with mNE but not with mPR3. In particular, P5 0-D and
P3 0-D interact with R36 and R35 of mNE, respectively, while
they are solvent exposed in the complex with mPR3. In mNE,
no hbond is observed for the charged groups of P1 0-D while
P2 0-R has one with S151-Oc. On the P side P3–D and P5–D
do not ﬁnd any basic aminoacid, while P5-D interacts with
R218 in mPR3 (G in mNE). In mNE-Pept7, P4-D interacts
with R217. It shows that P4, unlike P5 or P3 that are more
hydrophobic, can accommodate a negative residue. P2 0–E
and P3 0–E interact with R143 and R35, respectively. Pept7
has a sequence that matches very well the recognition sites of
mNE.
Fig. 8 summarizes the amino acids forming each of the bind-
ing pockets of mPR3 and mNE for the peptides we have tested.
Fig. 7. Interaction plot of Pept6 with mPR3 (A) and mNE (B). See
legend of Fig. 5.
Fig. 8. Map of the binding sites of mPR3 and mNE. Inventory of the
principal amino acids constituting the recognition sites of the enzyme;
residues interacting with side chains of the peptide are listed below the
peptide (black: hydrogen bonds, grey: hydrophobic interactions) and
backbone–backbone interactions are sketched above it.
Table 2
Preferred types of amino acids at the P sites of substrates (h,
hydrophobic; , negatively charged; +, positively charged, p, polar) of
hPR3 [11], hNE [11], mPR3 and mNE
P6 P5 P4 P3 P2 P1 P10 P20 P3 0 P40
hPR3 h h - h/p +  +
hNE h h h h h/p h
mPR3 +  h h h/+ h/p +  +
mNE h  h h h/p    
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polar, while S4, S3, S1, S40 are rather hydrophobic. In mNE: S4,
S20, S30, S40 and S50 are polar while S5 and the sites around the
cleavable bonds (S3–S1 0) are hydrophobic. Table 2 provides
the key to designing substrates speciﬁc for one or the other en-
zyme. The recognition sites in mouse and rat should be pretty
similar; the most noticeable diﬀerence is the presence of a thre-
onine at position 99 (instead of an asparagine) which mightrender P2 less polar. Wiesner et al. [13] measured kinetic
parameters for short hydrophobic peptides (AAPV, AAA
and AAPL) and showed that they are more eﬃciently cleaved
by mPR3, mNE and hNE than by hPR3. This is in agreement
with our description of the binding sites and in particular the
S2 pocket; the presence of K99 in hPR3 makes the S2 site polar
and positively charged while it is neutral, although polar, in
mPR3 (N99) and purely hydrophobic in mNE (L99) and
hNE (L99). Among the ﬁve inhibitors tested by Wiesner
et al. [13], Val15-aprotinin is the one exhibiting the most strik-
ing species-diﬀerence; it inhibits eﬃciently hNE (IC50
0.81 mol1) while it has very little or no eﬀect on mPR3,
mNE and hPR3 [13]. This can be explained by the fact that
the binding loop (YTGPCVARIIR) of and P5 0, which aproti-
nin contains an arginine in P2 0 Val15-render its interaction with
hPR3, mPR3 and mNE unfavorable. Indeed, unlike hNE, all
three proteases have an arginine at the S2 0 site (R143, cf. Figs.
1 and 8).4. Conclusion
Although highly identical, the sequences of mPR3 and hPR3
diﬀer in regions critical for substrate recognition (S2, S4). MD
simulations show that the peptide VADVKDR known to be
highly speciﬁc of – and eﬃciently cleaved by – hPR3 does
not interact properly with mPR3. Peptidic substrates eﬃciently
and speciﬁcally cleaved by hPR3 might be poor substrates of
mPR3.
The analysis of our simulations of fourteen enzyme-peptide
complexes allows us to draw a map of the binding sites of both
mPR3 and mNE (Fig. 8). It shows that the design or identiﬁ-
cation of substrates speciﬁc of one or the other of these two en-
zymes cannot rely on the studies performed on the human
enzymes [16,18–20]. Instead, we suggest sequence patterns (Ta-
ble 2), which should have a high binding aﬃnity and be speciﬁc
for either mPR3 or mNE. These results will help predicting the
binding aﬃnity of inhibitors, cleavable peptides or molecular
markers to mPR3 and mNE, and to identify intracellular tar-
gets of mPR3 and mNE. Enzymatic assays using extended pep-
tides such as, for example, pept4 (RDVARCRDRQEG) and
pept7 (GDVAVYEEN) will deﬁnitively establish the speciﬁcity
diﬀerences between the four enzymes. This is a prerequisite to
be able to design experiments and interpret observations from
murine models. Our work thereby contributes to the develop-
ment of a murine model for studying PR3-related inﬂamma-
tory pathologies
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